Onkológia 2/2018
Nové perspektívy v liečbe pokročilého a metastatického HR+ HER2- karcinómu prsníka
New perspectives in treatment of advanced and metastatic HR+ HER 2- breast cancer Approximately 70% of tumors express hormonal receptors (ER, PR), which are considered the main predictive response factor during hormonal therapy. Hormonal treatment represents an optimal basic choice for patients with advanced and metastatic hormone positive breast carcinoma without a threat of visceral crisis. Despite the benefits related to hormonal therapy, approximately 25% of patients are primarily resistant to hormonal therapy and the rest of the group will develop the resistance during hormonal treatment. Recently, intensive efforts have been devoted to identify mechanisms of resistance and targets capable of overcoing the resistance to hormonal therapy. An important role plays the ER, the possibilities of its activation and the cyclin. These are the goals whose impact has led to improved patients prognosis with metastatic hormone positive breast carcinoma.
Keywords: metastatic breast cancer, hormonal therapy, hormonal resistance, CDK4/6 inhibitors, systemic treatment
